Emcure Pharmaceuticals to increase gynaecology, derma portfolio for India market in FY26 | Company Business News-OxBig News Network

Pune-headquartered Emcure Pharmaceuticals plans to increase its gynaecology and dermatology product portfolio for the Indian market in FY26, the corporate’s prime govt stated on Thursday.

“In women’s health, we launched a portfolio of products in the menopause and PCOS segment [in FY25],” the corporate’s CEO and managing director Satish Mehta informed traders in a post-earnings name. “We are also in the process of deepening our presence in the gynaecology segment with further launches in FY26,” he added.

The agency, which was listed on the inventory exchanges in July 2024, reported a revenue after tax of ₹197 crore in Q4FY25, up 63% year-on-year. Revenue rose 19.5% YoY to ₹2,116 crore. 

The income development was pushed by 24.8% development in its home enterprise, and 15.6% development in its worldwide enterprise, Mehta stated.

“In Q4, we had a strong performance from our domestic business, which was led by women’s health and cardio and aided by dermatology,” Mehta stated.

The firm’s worldwide enterprise, which incorporates Canada, Europe and remainder of the world (RoW) markets, grew 15.6%.

“The key to success is execution and also the focus will be on improving our profitability,” Mehta informed traders within the name, referring to the corporate’s FY26 outlook. The firm is aiming for a income development of 13-14% in FY26, with about 150 bps margin enchancment. 

Also Read: Bain held on to Emcure after the IPO. Here’s what’s subsequent

Portfolio enlargement

Besides launching merchandise within the menopause and PCOS (polycystic ovary syndrome) section final fiscal 12 months, Emcure sharpened its focus within the dermatology section with the launch of its subsidiary, Emcutix Biopharmaceuticals. It launched two merchandise targeted on beauty skincare, a skin-tightening product and a urea-based moisturiser.

“Further pipeline of products will augment our basket of products over the next 12 months,” Mehta stated, including that the corporate can be seeing a variety of collaboration alternatives for its derma enterprise.

Emcure additionally built-in Sanofi’s cardiology portfolio into its enterprise for the Indian market. “Happy to inform that restructuring of our cardio-diabetic business is complete and we saw a return to normalization during the quarter. We expect this restructuring to drive growth going forward,” stated Mehta.

Emcure can be within the race for the first-wave of launches of weight-loss drug semaglutide in India subsequent 12 months, and stated it’s on observe for the launch. 

Also Read: How Donald Trump’s executive order on drug prices could hit Indian research companies 

Going ahead, the corporate will deal with complicated injectables, biosimilars and new drug supply routes for present molecules, Mehta stated.

“The key focus area will be CNS (central nervous system) and derma and we will also be working on ADCs (antibody drug conjugates),” he added.

Also Read: Biocon sees mid-teens revenue growth on biosimilars, generics push